Selection of matched unrelated donors moving forward: from HLA allele counting to functional matching.

Selection of matched unrelated donors moving forward: from HLA allele counting to functional matching. Hematology Am Soc Hematol Educ Program. 2019 Dec 06;2019(1):532-538 Authors: Fleischhauer K Abstract Matched unrelated donors (URD) are the most frequent source of stem cells for allogeneic hematopoietic cell transplantation (HCT) to date, with HCT performed mainly under conventional immunosuppression by methotrexate and cyclosporine. In this setting, every single allelic donor-recipient mismatch for HLA-A, -B, -C, -DRB1 (8/8), but not for HLA-DQB1, -DPB1, has a significant negative effect on overall survival (OS). When several 8/8 HLA-matched URD are available, donor age is the most important factor impacting OS. Moving forward from the traditional way of counting the number of donor-recipient HLA allele mismatches to biology-driven algorithms for functional matching has led to the unraveling of an association between permissive, low-risk HLA-DPB1 mismatches and improved outcome after URD HCT for malignant disease but not for nonmalignant disease. Functional HLA matching might prove to have increasing importance for URD selection in the era of new immunosuppressive regimens that have the potential to substantially reshuffle the role of HLA mismatches in URD HCT. PMID: 31808865 [PubMed - in process]
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Related Links:

The J.P. Morgan Healthcare conference runs every year in San Francisco, a big draw for the biotech industry, and many organizations take the opportunity to host events at the same time. Among these, the SENS Research Foundation has for the past few years hosted a pitch day in which biotech companies in the longevity industry, largely startups, present to that portion of the Bay Area investor community interested in funding the treatment of aging as a medical condition. I was there to present on progress at Repair Biotechnologies, and took some notes on the other companies as they talked about their work. Kimera Labs ...
Source: Fight Aging! - Category: Research Authors: Tags: Investment Source Type: blogs
Bone Marrow Transplantation, Published online: 20 January 2020; doi:10.1038/s41409-020-0789-5Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Bone Marrow Transplantation, Published online: 20 January 2020; doi:10.1038/s41409-020-0796-6Sinusoidal obstruction syndrome: a warning about autologous stem cell transplantation preceded by regimens containing oxaliplatin
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Bone Marrow Transplantation, Published online: 20 January 2020; doi:10.1038/s41409-020-0788-6Outcomes of conditioning with rabbit antithymocyte globulin and rituximab in haploidentical haematopoietic stem cell transplantation in patients with severe aplastic anaemia
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Respiratory tract infections are the second leading cause of mortality and morbidity worldwide1 and community acquired respiratory viruses (CARV) are the most common cause2. This statistic and the recent 2009 H1N1 influenza pandemic have raised awareness in national and transnational health authorities who support developing CARV epidemiological survey systems3 –6. These monitoring activities definitely contribute to health improvement and are extremely useful for national policy makers in identifying groups at high risk and for selecting influenza strains for yearly vaccine production.
Source: Journal of Infection - Category: Infectious Diseases Authors: Source Type: research
This study provides strong evidence that following a healthy lifestyle can substantially extend the years a person lives disease-free." Commentary on Recent Evidence for Cognitive Decline to Precede Amyloid Aggregation in Alzheimer's Disease I can't say that I think the data presented in the research noted here merits quite the degree of the attention that it has been given in the popular science press. It is interesting, but not compelling if its role...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Conclusions: The data show the microbial metabolome could have an impact on patients with GVHD vs. no GVHD. A better understanding of the role of the oral and gut microbiome in GVHD can give directions to move towards the development of innovative approaches for preventing GVHD following allo-HCT, reducing also antibiotic therapy. PMID: 31951695 [PubMed - in process]
Source: Central European Journal of Public Health - Category: International Medicine & Public Health Tags: Cent Eur J Public Health Source Type: research
Conclusions: Salvage chemotherapy (often with rituximab and radiotherapy), followed by HDT and stem cell transplantation, appears to be the standard real-world treatment for rrPMBCL. However, large prospective and retrospective studies are warranted to improve our knowledge of real-world treatment patterns. PMID: 31951774 [PubMed - as supplied by publisher]
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
This study adds to the body of evidence in describing incidence and type of cardiac events experienced by an allogeneic and autologous HSCT population at one institution from 2012-2017. Sixty-five patients (9.8%) experienced cardiac events, including atrial arrhythmia (N = 39), acute heart failure (N = 9), acute coronary syndrome (N = 7), new onset hypertension (N = 9), with a few instances of bradycardia, ventricular arrhythmia, pericardial effusion, and pericarditis. Our multivariable regression analysis identified age (older), creatinine (higher) and history of coronary artery disease to significantly correlate with ris...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More than 2 billion people are infected with hepatitis B virus (HBV) worldwide. The prevalence of chronic HBV infection is high (6.2%) in the Western Pacific and African regions [1]. Many researchers are aware of the risk of HBV reactivation in previously infected patients during immunosuppressive therapies such as chemotherapy, rituximab therapy and glucocorticoids [2,3]. The prevalence of hepatitis B core antibody (HBcAb) ranges from 5% in Western countries to>50% in Far Eastern countries [4 –6].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Biology | Cancer & Oncology | Education | Hematology | Methotrexate | Restasis | Stem Cell Therapy | Stem Cells | Transplants | Universities & Medical Training